ABSTRACT
INTRODUCTION
Cystic fibrosis (CF) gene therapy is being pioneered in the lung because in addition to being the organ most severely affected by CF, it is directly accessible to aerosolized reagents. While showing promise, current vectors only show partial and transient correction of the CF phenotype (see Reference 1 and references therein). Therefore studies are aimed at improving the existing gene therapy protocols and designing new ones to overcome the physical and biological blocks to gene therapy (for review see Reference 3) .
To facilitate bacterial cloning of cystic fibrosis transmembrane conductance regulator (CFTR) , Gregory et al. (5) introduced a neutral mutation into the CFTRgene (936T →C) that silences a cryptic bacterial promoter. This derivative of CFTR(936C) is used in most current CF gene therapy vectors, and thus the single-base substitution (936T →C) potentially allows discrimination between transgene and endogenous CFTR . By designing primers for the polymerase chain reaction (PCR) that will specifically amplify either the 936C or 936T forms of CFTR , an amplification refractory mutation system (ARMS) assay (11) (also known as allele-specific PCR; see References 4, 12, 13 and 15) can be used to discriminate these two species of template (see Figure 1 ). An attraction of such an assay is that it can be used on transfected samples from any source, expressing either wild-type or mutant CFTR , irrespective of the particular CFTRmutations present. We describe the development and use of an ARMS assay to distinguish endogenous (936T) from transgene (936C) CFTRusing a LightCycler ™ Instrument (14) , allowing rapid real-time quantitation of the specific reverse transcription (RT)-PCR products.
MATERIALS AND METHODS
Template DNA for the ARMS assay was prepared either by linearizing plasmids encoding CFTRcDNA or from RNA isolated from transiently transfected cultured cells, which had been DNase-treated (Boehringer Mannheim, East Sussex, UK) to remove contaminating gene therapy vector. cDNA synthesis was performed using a Random Primer cDNA Synthesis Kit (Boehringer Mannheim) following the manufacturer's instructions.
The ARMS assay consists of two separate amplification reactions for Temperature profiles for amplification were optimized for each set of primers: ( i ) For ARMS-A, 95°C for 8 s followed by 60 ×(94°C for 0 s, 56°C for 0 s and 74°C for 4 s). The temperature ramp rate was 20°C/s, except for the transition from 56°to 74°C, which was 6°C/s. ( ii ) For ARMS-G, the conditions are the same as for ARMS-A with the exception that the annealing temperature was 58°not 56°C, and the ramp rate from 58°to 74°C was 8°C/s. At the end of each extension step (74°C), the fluorescence of each sample was measured to allow quantitation of the PCR. After the PCR was complete, the products were subjected to a temperature gradient from 74°to 95°C at 0.2°C/s with continuous fluorescence monitoring to produce a melting profile of the Vol. 27, No. 1 (1999)
BioTechniques 123 b The assay measures the amount of transgene present using the ARMS-G and S1U primers as described-the predicted amounts are shown.
c ARMS-A and S1U primers are used to quantify endogenousCFTR, and the predicted amounts are shown. Note that in Sample 8, the excess of transgene CFTRpresent (10 9 copies) causes an apparent increase in endogenous CFTR .
products. Quantitative analysis was performed on the LightCycler data according to manufacturer's instructions; standard controls of known concentration were included in each run to produce a standard curve, allowing quantitation of templates. Identical template concentrations are detected amplifying exponentially at equivalent number of cycles in separate reactions (data not shown). However, to minimize errors, a standard curve was produced for each separate reaction to allow quantitation of the unknown samples.
RESULTS
The assay was used to quantitate either endogenous or transgene CFTR cDNA. cDNA samples from cells expressing endogenous human CFTR were quantified using primers S1U and ARMS-A. Figure 2 shows quantitation of a cDNA sample of endogenous CFTRrelative to known controls. The single unknown sample in this reaction was predicted to contain 2.1 ×10 6 copies of endogenous CFTR (mean squared error of concentration of 1.45). After the conclusion of the quantitative amplification reactions, the products were melted (as outlined in Materials and Methods). The melting is monitored with fluorescence, which is lost when the double-strand products melt apart. As different DNA products melt at different temperatures, distinguishing genuine products from primer dimers or nonspecific products is possible. The assay could distinguish as few as 10 2 -10 3 copies of CFTR , below which nonspecific amplification of primer-dimers was seen (for example, see Table 1 ).
The main strength of this assay however is not in its sensitivity but in its ability to distinguish 936C (transgene) from 936T (endogenous) CFTR . Figure 3 shows an example of this. CFTR ( 10 5 copies) was amplified with primers (S1U and ARMS-G) specific for transgene CFTR . One sample contains 10 5 copies of 936C transgene CFTR , while the other had an identical concentration of 936T endogenous CFTR(two H 2 O controls are included). Only the transgene CFTR is amplified, showing that the PCR is specific for transgene sequence.
The assay could be used to analyze a mixture of both endogenous and transgene CFTR , such as we might find in a cDNA sample from a clinical trial. To model this situation, samples of a fixed concentration of endogenous CFTR cDNA were seeded with known concentrations of transgene CFTR . The absolute quantities of both species were assayed with their respective specific
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Vol. 27, No. 1 (1999) Figure 2 . Quantitation of endogenous CFTR . A screen of the LightCycler quantitation software for six different amounts of endogenous CFTR ; also included is a sample of unknown concentration. The primers used (ARMS-A and S1U) are specific for the endogenous CFTR (936T). The panels are labeled (from top left clockwise): 'Files', the particular reaction selected. 'Samples to Graph', samples are as follows: samples 1-6 contain various control quantities of endogenous CFTR , presented as absolute numbers of CFTRmolecules; sample 1 = 10 9 , sample 2 = 10 8 , sample 3 = 10 7 , sample 4 = 10 6 , sample 5 = 10 5 and sample 6 = 10 4 ; sample 8 contains an unknown quantity of endogenous CFTR(sample 7 is not shown). 'Concentration', the predicted concentration based upon the standard curve (bottom left) for all samples, including those of known concentration; sample 8 is predicted to contain 2.1 ×10 6 copies of CFTR . The two graphs demonstrate the following: ( i ) 'Flo v. Cycle #' shows the SYBR Green I fluorescence (relative units) on the y-axis and PCR cycle number on the x-axis; and ( ii ) 'Log Flo vs. Cycle #' shows log fluorescence against PCR cycle number. 'Crossing Point vs. Log (Concentration)', the standard curve for this data with the six known controls; the actual data points are shown in red, and the standard curve is shown in green. The mean squared error of log (concentration) of the data vs. the standard curve is shown in red immediately right of the graph (in this case 0.16; hence, the mean squared concentration error is 1.45). The 'Temperature Chart', the temperature profile of the entire PCR.
primers. Table 1 shows the results of the assay relative to the known concentrations used. This demonstrates the ability of our assay to compare levels of cDNA in a mixture of the two species (endogenous and transgene).
DISCUSSION
Detection of CFTRtranscripts using RT-PCR is a standard method for assessing the efficiency of gene therapy. In experiments using CF mouse models, the primers can be designed specifically for the human sequence, thereby eliminating problems associated with endogenous CFTR . In human cell lines or in clinical trials, endogenous and exogenous CFTRwill be co-amplified, as the template CFTRsequences are identical. Mayall and Coutelle (10) Figure 2 ). SYBR Green I fluorescence (in relative units) is plotted on the y-axis against PCR cycle number on the x-axis. The primers used in this reaction are ARMS-G and S1U; hence, this reaction is specific for the transgene (936C) CFTR . Four samples are shown: two are H 2 O controls, and these seem to amplify (primer-dimer amplification) at approximately the same position as 10 5 copies of endogenous CFTR ; whereas 10 5 copies of transgene amplify over 10 cycles earlier in the reaction. Thus the assay discriminates between transgene and endogenous CFTR . therapy vector to distinguish transgene signal from both DNA and endogenous message in RT-PCRs; however, such mechanisms limit vector choice and rely on the presumption of efficient splicing. The presence of the T →C base change, at position 936 in the cDNA, allows another way of discriminating between genomic-and vector-derived expression by virtue of the fortuitous creation of a Fok I site in 936C CFTR . Hence, appropriate PCR products can be digested with Fok I, and the resulting fragments quantified to determine the ratio of genomic-to-vector transcript. However, this is laborious and relies on full cleavage of the 936C product. A different restriction assay developed by Hart et al. (6) , introduced two silent mutations into CFTRto allow restriction digests of PCR products for quantitation. Proofreading PCR (2) could also be used to make the discrimination; although, variation in efficiency of polymerase proofreading could compromise quantitation.
The ARMS assay makes use of the single base pair difference engineered into transgene CFTRcDNA (5) in a simple and direct way to prevent amplification of the nonspecific product. An excess of 10 3 copies of one template species over the other could be detected, beyond which, mis-amplification of the nonspecific template was seen. This is in agreement with published mis-incorporation rates of TaqDNA polymerase (7, 8) . Fluorescent monitoring of PCR can be optimized to enable detection of a single-template molecule (9) ; although, the sensitivity of our assay is limited because of constraints in primer design and in our use of SYBR Green I for PCR product detection. However, it provides a quantitative assessment of transgene mRNA levels both in absolute terms and in comparison with the level of endogenous CFTR in the range and relative ratio likely to be encountered experimentally and in clinical trials. The analysis of 24 samples (including controls) takes less than 20 min, allowing a simple and rapid way to quantify CFTRcDNA from in vitro and in vivo experiments.
